GlassScriptPhysician profile
Chunsu Jiang
NPI 1750736542
$3,644.57
in general payments reported to CMS, 2019-2025
23 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223 · 2022: $268 · 2023: $802 · 2024: $1,283 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,154.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,479.38 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $305.41 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Medtronic, INC. | $294.99 | 2022-2025 | Interstim |
| Genzyme Corporation | $231.15 | 2023-2025 | |
| Boston Scientific Corporation | $203.22 | 2021-2023 | |
| Qol Medical, LLC | $153.90 | 2024-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $153.70 | 2023-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $141.27 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $87.55 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $76.23 | 2023-2024 | Ocaliva |
| Gilead Sciences, INC. | $74.24 | 2021 | |
| Pfizer INC. | $74.06 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $67.09 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $63.27 | 2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.50 | 2023-2025 | Xifaxan, Trulance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $33.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $32.80 | 2024-2025 | Sutab, Suflave |
| Celgene Corporation | $31.53 | 2024 | Zeposia |
| Novo Nordisk INC | $25.62 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $21.54 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $16.11 | 2024 | |
| Medline Industries LP | $15.07 | 2023 | |
| Merck Sharp & Dohme LLC | $14.20 | 2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chunsu Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.